
Congrats to @Tagworkspharma on this significant milestone! Great news for patients as the Company enters clinical development of their Phase 1 trial of TGW101, a first-in-class antibody drug-conjugate targeting tumor associated glycoprotein 72 (TAG-72) in advanced #solidtumors.
We’re thrilled to announce the initiation of our Phase 1 clinical trial evaluating TGW101, an #ADC developed with our Click-to-Release treatment platform, in patients with advanced #solidtumors. Learn more: bit.ly/4jrAErw
















